The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosis

Trial Profile

The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top